Crispr Therapeutics AG

Crispr Therapeutics AG is a biotechnology company specializing in the development of gene-editing therapies aimed at treating serious and often life-threatening diseases. Leveraging the CRISPR/Cas9 gene-editing platform, the company focuses on precisely modifying specific DNA sequences to address both rare and common disorders. Its therapeutic pipeline spans several key areas, including hemoglobinopathies like sickle cell disease and beta thalassemia, immuno-oncology applications for cancer treatment, autoimmune diseases, and type 1 diabetes. The company’s most advanced product, Casgevy (exagamglogene autotemcel), developed in collaboration with Vertex Pharmaceuticals, has gained regulatory approval for treating severe blood disorders in multiple regions. Headquartered in Zug, Switzerland, Crispr Therapeutics is recognized as a pioneer in gene-based medicines and continues to push the boundaries of medical innovation by translating cutting-edge science into accessible therapies for patients worldwide.